Salomon Manier

10.1k total citations · 2 hit papers
158 papers, 3.4k citations indexed

About

Salomon Manier is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Salomon Manier has authored 158 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Hematology, 70 papers in Oncology and 68 papers in Molecular Biology. Recurrent topics in Salomon Manier's work include Multiple Myeloma Research and Treatments (111 papers), Protein Degradation and Inhibitors (32 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Salomon Manier is often cited by papers focused on Multiple Myeloma Research and Treatments (111 papers), Protein Degradation and Inhibitors (32 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Salomon Manier collaborates with scholars based in France, United States and Italy. Salomon Manier's co-authors include Irene M. Ghobrial, Aldo M. Roccaro, Antonio Sacco, Xavier Leleu, Karma Z. Salem, Michele Moschetta, Siobhan Glavey, Jihye Park, Yawara Kawano and Daisy Huynh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Salomon Manier

149 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomic complexity of multiple myeloma and its clinical implications

2016 354 citations Salomon Manier, Karma Z. Salem et al. profile →
Multiple myeloma

2024 72 citations Paola Neri, Nizar J. Bahlis et al. Nature Reviews Disease Primers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Salomon Manier France	29	2.1k	1.9k	1.3k	719	531	158	3.4k
Klaus H. Metzeler Germany	29	2.3k 1.1×	2.6k 1.4×	1.0k 0.8×	912 1.3×	663 1.2×	115	4.3k
Patricia Maiso United States	24	2.0k 0.9×	1.3k 0.7×	810 0.6×	761 1.1×	600 1.1×	64	3.1k
Hetty E. Carraway United States	35	1.7k 0.8×	1.4k 0.7×	1.1k 0.8×	399 0.6×	488 0.9×	212	3.6k
Els Van Valckenborgh Belgium	36	1.8k 0.9×	1.3k 0.7×	1.1k 0.8×	677 0.9×	610 1.1×	77	2.9k
Antonio Sacco United States	33	2.6k 1.2×	1.6k 0.8×	1000 0.8×	1.2k 1.7×	783 1.5×	111	4.3k
Bruno Paiva Spain	36	2.6k 1.2×	3.4k 1.8×	1.9k 1.5×	241 0.3×	804 1.5×	157	4.7k
Maria Teresa Petrucci Italy	32	2.2k 1.0×	2.5k 1.3×	1.9k 1.4×	197 0.3×	1.2k 2.2×	156	4.1k
Thomas Kindler Germany	27	1.5k 0.7×	1.7k 0.9×	615 0.5×	257 0.4×	342 0.6×	78	3.0k
Nikolas von Bubnoff Germany	31	1.1k 0.5×	2.0k 1.0×	1.1k 0.9×	537 0.7×	708 1.3×	138	4.1k
Thomas Prébet France	32	2.0k 0.9×	2.9k 1.5×	735 0.6×	321 0.4×	596 1.1×	171	4.2k

Countries citing papers authored by Salomon Manier

Since Specialization

Citations

This map shows the geographic impact of Salomon Manier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salomon Manier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salomon Manier more than expected).

Fields of papers citing papers by Salomon Manier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salomon Manier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salomon Manier. The network helps show where Salomon Manier may publish in the future.

Co-authorship network of co-authors of Salomon Manier

This figure shows the co-authorship network connecting the top 25 collaborators of Salomon Manier. A scholar is included among the top collaborators of Salomon Manier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salomon Manier. Salomon Manier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hueso, Thomas, Grégory Lazarian, Adrien Chauchet, et al.. (2025). Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis. eJHaem. 6(2). e70019–e70019.

Sidana, Surbhi, Joaquín Martínez‐López, Albert Oriol, et al.. (2025). POSTER: MM-1070 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Survival Subgroup Analyses. Clinical Lymphoma Myeloma & Leukemia. 25. S307–S307.

Touzeau, Cyrille, Meral Beksaç, Evangelos Terpos, et al.. (2024). Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology. 42(16_suppl). 7506–7506. 7 indexed citations

Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations

Touzeau, Cyrille, Aurore Perrot, Cyrille Hulin, et al.. (2024). Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 143(20). 2029–2036. 28 indexed citations

Neri, Paola, Nizar J. Bahlis, Evangelos Terpos, et al.. (2024). Multiple myeloma. Nature Reviews Disease Primers. 10(1). 72 indexed citations breakdown →

Façon, Thierry, Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).. Journal of Clinical Oncology. 42(16_suppl). 7500–7500. 3 indexed citations

Manier, Salomon, Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ. Clinical Lymphoma Myeloma & Leukemia. 24. S290–S291. 2 indexed citations

Nooka, Ajay K., Cesar Rodriguez, María‐Victoria Mateos, et al.. (2023). Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. Cancer. 130(6). 886–900. 36 indexed citations

10.

Raab, Marc S., Elena Zamagni, Salomon Manier, et al.. (2023). Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results. SHILAP Revista de lepidopterología. 4(4). 1117–1131. 12 indexed citations

11.

Bahlis, Nizar J., Luciano J. Costa, Thierry Façon, et al.. (2023). Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH). PubMed. 5(2-3). 112–121. 1 indexed citations

12.

Façon, Thierry, Xavier Leleu, & Salomon Manier. (2023). How I treat multiple myeloma in geriatric patients. Blood. 143(3). 224–232. 21 indexed citations

13.

Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398. 2 indexed citations

14.

Beauvais, David, Ibrahim Yakoub‐Agha, Suman Mitra, et al.. (2021). Effective anti-BCMA retreatment in multiple myeloma. Blood Advances. 5(15). 3016–3020. 27 indexed citations

15.

Shen, Yu J., Yuji Mishima, Jiantao Shi, et al.. (2020). Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 137(17). 2360–2372. 32 indexed citations

16.

Kurdi, Ahmed T., Siobhan Glavey, Natalie Bezman, et al.. (2018). Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics. 17(7). 1454–1463. 70 indexed citations

17.

Takagi, Satoshi, Shokichi Tsukamoto, Jihye Park, et al.. (2018). Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation. Clinical Cancer Research. 24(10). 2430–2439. 45 indexed citations

18.

Tsukamoto, Shokichi, Marianne Bengtson Løvendorf, Jihye Park, et al.. (2018). Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia. 32(8). 1739–1750. 33 indexed citations

19.

Boyle, Eileen M., Guillemette Fouquet, Salomon Manier, et al.. (2014). Myélome, IMiD et thrombose. 20(1). 15–22. 1 indexed citations

20.

Roccaro, Aldo M., Antonio Sacco, Xiaojing Jia, et al.. (2012). Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia. Clinical Cancer Research. 18(24). 6609–6622. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact